Community Shares | August 12th 2024
This week’s articles: Researchers have developed a new app, SenseToKnow, which aims to enhance ASD screening for toddlers; A recent study has found a significant association between parental depression and an increased risk of developmental disorders in children, including ASD, ADHD, tic disorders, and various developmental delays; The U.S. Senate has advanced the Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2024, a key piece of legislation aimed at enhancing autism research and services; Don’t miss an enlightening webinar exploring the impact of Gut-Brain Axis Therapeutics (GBAT) on autism, featuring firsthand accounts from four parents whose children with autism participated in groundbreaking clinical trials.
High Incidence of Arthritis and Autoimmune Diseases Found in Children with PANS
A new original investigation featured in JAMA Network has provided the largest longitudinal analysis of pediatric acute-onset neuropsychiatric syndrome (PANS) to date, revealing a high incidence of immune activation, arthritis, and autoimmune diseases among patients.
Increased Physical Disease Risk Discovered in Individuals with Autism
Danish researchers have revealed that children and adults with autism spectrum disorder (ASD) face a notably higher immediate risk of developing a wide range of physical diseases compared to those without ASD.
Community Shares | August 5th 2024
This week’s articles: A recent study examined the neurodevelopment of preschool-age children in the U.S. who were exposed to the Zika virus (ZIKV) in utero but did not have microcephaly or other signs of congenital Zika syndrome; New research indicates that ADH-503, an experimental cancer drug, shows promise in alleviating cognitive difficulties associated with Rett syndrome, a rare disorder linked to autism; An analysis of how a mother’s diet during pregnancy influences the risk of autism in her child has provided valuable new insights; Jaguar Gene Therapy has announced that the FDA has approved the Phase I clinical trial for JAG201, a gene therapy targeting ASD caused by SHANK3 mutations and Phelan-McDermid syndrome.
Systematic Review Links Environmental Pollutants to Autism and Other Neurodevelopmental Disorders
A new scientific review claims to be the first to systematically examine the impact of various environmental pollutants on autism spectrum disorder (ASD) and other neurodevelopmental disorders (NDDs).
Enzyme Activity and Methylmercury Exposure May Impact Early Brain Development
Glyoxalase 1 (Glo1) is an important enzyme that helps break down methylglyoxal (MGO), a harmful substance produced in the body and found in the environment.
